Create a narrative

Spero Therapeutics Community

NasdaqGS:SPRO Community

1 Narratives written by author
0 Comments on narratives written by author
21 Fair Values set on narratives written by author

Create a narrative

Spero Therapeutics

AN

AnalystConsensusTarget

Consensus Narrative from 2 Analysts

Successful Phase III Trial Will Redefine Treatment For Complicated UTIs

Key Takeaways Successful PIVOT-PO trial and regulatory approval could propel revenue growth, leveraging a strategic partnership with GSK for commercialization. Focus on tebipenem HBr and solid cash reserves may boost investor confidence and optimize future financial performance.

US$5.00

FV

88.2% undervalued

-12.18%

Revenue growth p.a.

0

0

17

6 days ago